Signals, Powered By EquityPandit
The US health regulator has provided its final approval to Lupin for marketing generic Voriconazole tablets as well as oral suspension for treatment of fungal infections in the American market.
Lupin has said in a BSE filing that the US subsidiary of company Gavis Pharmaceuticals LLC has got the final approval to market “its Voriconazole tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL from the United States Food and Drug Administration (FDA).”
It further said that the company’s products are generic versions of PF Prism C.V’s Vfend tablets and Vfend oral suspension in the same strengths.
